Knott David M Jr Grows Position in Ultragenyx Pharmaceutical Inc. $RARE

Knott David M Jr increased its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 8.3% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 52,000 shares of the biopharmaceutical company’s stock after purchasing an additional 4,000 shares during the period. Ultragenyx Pharmaceutical makes up 0.9% of Knott David M Jr’s investment portfolio, making the stock its 21st largest holding. Knott David M Jr owned 0.05% of Ultragenyx Pharmaceutical worth $1,891,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Creative Planning purchased a new stake in shares of Ultragenyx Pharmaceutical during the second quarter worth about $454,000. Police & Firemen s Retirement System of New Jersey increased its position in shares of Ultragenyx Pharmaceutical by 7.6% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 34,592 shares of the biopharmaceutical company’s stock worth $1,258,000 after acquiring an additional 2,458 shares during the period. Geode Capital Management LLC raised its stake in Ultragenyx Pharmaceutical by 4.0% in the second quarter. Geode Capital Management LLC now owns 1,712,931 shares of the biopharmaceutical company’s stock worth $62,291,000 after buying an additional 66,394 shares in the last quarter. S&CO Inc. raised its stake in shares of Ultragenyx Pharmaceutical by 24.7% during the 2nd quarter. S&CO Inc. now owns 25,255 shares of the biopharmaceutical company’s stock worth $918,000 after acquiring an additional 5,000 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at approximately $309,000. 97.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have weighed in on RARE. Wells Fargo & Company started coverage on shares of Ultragenyx Pharmaceutical in a research report on Monday, October 20th. They issued an “overweight” rating and a $65.00 price objective for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, October 8th. TD Cowen reduced their target price on shares of Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Truist Financial lowered their target price on shares of Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Finally, Canaccord Genuity Group decreased their price target on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating for the company in a report on Friday, August 8th. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $82.75.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 7,942 shares of the stock in a transaction that occurred on Monday, October 13th. The stock was sold at an average price of $31.51, for a total value of $250,252.42. Following the completion of the transaction, the chief financial officer directly owned 98,227 shares of the company’s stock, valued at $3,095,132.77. This represents a 7.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Karah Herdman Parschauer sold 2,450 shares of the business’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $31.17, for a total value of $76,366.50. Following the sale, the executive vice president directly owned 73,271 shares in the company, valued at approximately $2,283,857.07. The trade was a 3.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 10,456 shares of company stock valued at $328,486. 5.50% of the stock is owned by insiders.

Ultragenyx Pharmaceutical Trading Up 0.5%

Shares of RARE stock opened at $33.08 on Monday. The company’s fifty day simple moving average is $31.63 and its 200-day simple moving average is $32.62. The company has a market cap of $3.19 billion, a PE ratio of -5.98 and a beta of 0.30. Ultragenyx Pharmaceutical Inc. has a 52 week low of $25.81 and a 52 week high of $50.00.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.58). Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The company had revenue of $159.93 million during the quarter, compared to analyst estimates of $167.42 million. During the same quarter last year, the business posted ($1.40) EPS. Ultragenyx Pharmaceutical’s quarterly revenue was up 14.6% compared to the same quarter last year. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.